BIODETEGO
BioDetego is developing, VASPfore, a new biomarker test for selecting cancer treatment protocols. The VASP marker provides information that will direct chemotherapy to high risk patients who will likely benefit from treatment while preventing costly and harmful treatment of low risk patients. BioDetego predicts that the VASPfore will provide payors enormous savings (>$150MM/year) by reducing total treatment costs. The company is led by David Zuzga, Ph.D., Founder and CEO, a research scientist with expertise in cell and molecular biology at La Salle University & Giovanni M. Pitari, M.D., Ph.D. Founder and CSO, a physician and research scientist with expertise in Translational Oncology.
BIODETEGO
Industry:
Biotechnology Clinical Trials Health Diagnostics
Founded:
2012-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.biodetego.com
Total Employee:
1+
Status:
Active
Total Funding:
50 K USD
Technology used in webpage:
Google Apps For Business Pound Sterling Japanese Yen Wix Wix DNS
Founder
Investors List
BioAdvance
BioAdvance investment in Seed Round - BioDetego
Ben Franklin Technology Partners of Southeastern Pennsylvania
Ben Franklin Technology Partners of Southeastern Pennsylvania investment in Seed Round - BioDetego
Official Site Inspections
http://www.biodetego.com Semrush global rank: 4.56 M Semrush visits lastest month: 910
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.107
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
